303 related articles for article (PubMed ID: 15693889)
1. PDGFRalpha- and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features.
Pauls K; Merkelbach-Bruse S; Thal D; Büttner R; Wardelmann E
Histopathology; 2005 Feb; 46(2):166-75. PubMed ID: 15693889
[TBL] [Abstract][Full Text] [Related]
2. [Gastrointestinal stromal tumors carrying PDGFRalpha mutations occur preferentially in the stomach and exhibit an epithelioid or mixed phenotype].
Wardelmann E; Pauls K; Merkelbach-Bruse S; Hrychyk A; Losen I; Hohenberger P; Büttner R; Pietsch T
Verh Dtsch Ges Pathol; 2004; 88():174-83. PubMed ID: 16892550
[TBL] [Abstract][Full Text] [Related]
3. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
Zheng S; Chen LR; Wang HJ; Chen SZ
Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.
Debiec-Rychter M; Wasag B; Stul M; De Wever I; Van Oosterom A; Hagemeijer A; Sciot R
J Pathol; 2004 Apr; 202(4):430-8. PubMed ID: 15095270
[TBL] [Abstract][Full Text] [Related]
5. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated.
Penzel R; Aulmann S; Moock M; Schwarzbach M; Rieker RJ; Mechtersheimer G
J Clin Pathol; 2005 Jun; 58(6):634-9. PubMed ID: 15917417
[TBL] [Abstract][Full Text] [Related]
6. KIT and PDGFRalpha mutational analyses of mixed cell-type gastrointestinal stromal tumours.
Wong NA; Mangwana S
Histopathology; 2007 Dec; 51(6):758-62. PubMed ID: 18042065
[TBL] [Abstract][Full Text] [Related]
7. PDGFRalpha gene mutation and protein expression in gastrointestinal stromal tumors.
Chang HM; Ryu MH; Lee H; Jang SJ; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
Oncology; 2008; 74(1-2):88-95. PubMed ID: 18547963
[TBL] [Abstract][Full Text] [Related]
8. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
[TBL] [Abstract][Full Text] [Related]
9. Multiple gastrointestinal stromal tumors: Clinicopathologic and genetic analysis of 12 patients.
Kang DY; Park CK; Choi JS; Jin SY; Kim HJ; Joo M; Kang MS; Moon WS; Yun KJ; Yu ES; Kang H; Kim KM
Am J Surg Pathol; 2007 Feb; 31(2):224-32. PubMed ID: 17255767
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
11. Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series.
Gomes AL; Gouveia A; Capelinha AF; de la Cruz D; Silva P; Reis RM; Pimenta A; Lopes JM
J Clin Pathol; 2008 Feb; 61(2):203-8. PubMed ID: 17827398
[TBL] [Abstract][Full Text] [Related]
12. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations.
Perrone F; Tamborini E; Dagrada GP; Colombo F; Bonadiman L; Albertini V; Lagonigro MS; Gabanti E; Caramuta S; Greco A; Torre GD; Gronchi A; Pierotti MA; Pilotti S
Cancer; 2005 Jul; 104(1):159-69. PubMed ID: 15929122
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
Miettinen M; Sobin LH; Lasota J
Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
[TBL] [Abstract][Full Text] [Related]
14. Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA.
de Raedt T; Cools J; Debiec-Rychter M; Brems H; Mentens N; Sciot R; Himpens J; de Wever I; Schöffski P; Marynen P; Legius E
Gastroenterology; 2006 Dec; 131(6):1907-12. PubMed ID: 17087943
[TBL] [Abstract][Full Text] [Related]
15. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
[TBL] [Abstract][Full Text] [Related]
16. Comparative ultrastructural analysis and KIT/PDGFRA genotype in 125 gastrointestinal stromal tumors.
Agaram NP; Baren A; Arkun K; Dematteo RP; Besmer P; Antonescu CR
Ultrastruct Pathol; 2006; 30(6):443-52. PubMed ID: 17182437
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic targets in gastrointestinal stromal tumors].
Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
[TBL] [Abstract][Full Text] [Related]
18. Genetic and pathologic characteristics of gastrointestinal stromal tumors in extragastric lesions.
Cho S; Kitadai Y; Yoshida S; Tanaka S; Yoshihara M; Yoshida K; Chayama K
Int J Mol Med; 2006 Dec; 18(6):1067-71. PubMed ID: 17089009
[TBL] [Abstract][Full Text] [Related]
19. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
[TBL] [Abstract][Full Text] [Related]
20. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size.
Rossi S; Gasparotto D; Toffolatti L; Pastrello C; Gallina G; Marzotto A; Sartor C; Barbareschi M; Cantaloni C; Messerini L; Bearzi I; Arrigoni G; Mazzoleni G; Fletcher JA; Casali PG; Talamini R; Maestro R; Dei Tos AP
Am J Surg Pathol; 2010 Oct; 34(10):1480-91. PubMed ID: 20861712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]